<DOC>
	<DOC>NCT00808392</DOC>
	<brief_summary>This study will investigate safety and immunogenicity of a monovalent conjugated vaccine against Haemophilus influenzae type b in healthy children aged 2 to 4 months in China.</brief_summary>
	<brief_title>Safety and Immunogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Haemophilus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Infants of either sex, aged 2 4 months In good health as determined by: medical history physical examination clinical judgment of the investigator; Available for all visits scheduled in the study and able to comply with all study regulations For whom written informed consent has been obtained from at least one parent or legal guardian Parent or legal guardian is unwilling or unable to give written informed consent to participate in study Infants who have received any other Haemophilus influenzae type b immunization dose before Infants who presented a previous disease potentially related to Haemophilus influenzae type b Infants who had household contact and/or intimate exposure in the previous 30 days to an individual with ascertained Haemophilus influenzae type b disease Premature (before 37th week of gestation) or birth weight less than 2500 g History of anaphylactic shock, asthma, urticaria or other allergic reaction after previous vaccinations or hypersensitivity to any vaccine component Fever ≥ 38.0 °C (axillary body temperature) or/and significant acute or chronic infection requiring systemic antibiotic or antiviral therapy within the past 7 days before enrollment Subjects with any serious chronic disease such as cardiac, neurological, metabolic, hematologic, or neoplastic disease Known/suspected immunodeficiency, or autoimmune disease, or any immunologic disorder Subjects with any neurological disorder, e.g., epilepsy or history of seizure disorder Subjects with a clinically significant genetic anomaly Treatment with corticosteroids or other immunosuppressive drugs Any previous treatment with parenteral immunoglobulin preparation, blood products, and/or plasma derivatives Any vaccination administered within one week (7 days) before enrollment and/ or any planned administration of any vaccine outside the Chinese routine vaccination program. Participation in any other investigational trial simultaneously Planned surgery during the study period Any condition, which, in the opinion of the investigator, might interfere with the evaluation of the study objective</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>4 Months</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>vaccine</keyword>
	<keyword>prevention</keyword>
	<keyword>haemophilus influenzae type b</keyword>
	<keyword>children</keyword>
</DOC>